RxDoctor Payments Data

Nikunjkumar Modi, MD

Psychiatry · Florence, SCNPI 1003131343

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $119,241 of the $133,373 with a category attached, or 89.4%. AbbVie accounts for 63.7% of it on its own, with 14 other manufacturers making up the rest. Among psychiatry clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$133,373in general payments, 2019–2025

Across 398 payments — averaging $335.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$85K
  • Teva Pharmaceuticals USA, Inc.$44K
  • E.r. Squibb & Sons, L.L.C.$2K
  • Otsuka America Pharmaceutical, Inc.$630
  • Alkermes, Inc.$449
  • Johnson & Johnson$371
  • plus $652 from 9 others

What the payments were for

  • Consulting fees$1,8401%
  • Speaking & faculty fees$119,24189%
  • Travel & lodging$5,1144%
  • Food & beverage$7,0495%
  • Education$1280%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$133,373 in reported general payments places this provider in the 95th percentile of 624 psychiatry providers in South Carolina.

See all psychiatry providers in South Carolina

Medicare billing

Part B allowed, 2024
$4,732
Medicare patients
16
Services billed
60

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate22$72,369
Abilify MaintenaAripiprazole18$52,403
Risperdal ConstaRisperidone Microspheres39$34,276
VraylarCariprazine Hcl17$24,662
Clozapine13$4,024
Aripiprazole35$1,403
Duloxetine Hcl47$1,068
Quetiapine Fumarate43$782
Gabapentin23$706
Mirtazapine40$663
Trazodone Hcl67$576
Buspirone Hcl34$497
Divalproex Sodium21$430
Bupropion XlBupropion Hcl27$420
Venlafaxine Hcl ErVenlafaxine Hcl39$354

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Risperdal Consta$371$106,64561 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$630$52,40318 claims
AbbVieVraylar$84,983$24,66217 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 624 psychiatry providers in South Carolina.

Other psychiatry in Florence

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →